Drug repurposing service providers market is projected to grow at an annualized rate of 14.7% / till 2030

Author : kevin987
Publish Date : 2021-03-19 05:37:22


Drug repurposing service providers market is projected to grow at an annualized rate of 14.7% / till 2030

Roots Analysis has done a detailed study on Drug Repurposing Service Providers Market, 2020-2030.”

covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

 

To order this 250+ page report, which features 100+ figures and 140+ tables, please visit this https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Key Market Insights

  • More than 60 industry players across the world are presently engaged in providing services for the repurposing of therapeutics
  • The dataset features a variety of CRO, big data / analytics and technology-based service providers, offering repurposing services by using different type of repurposing approaches and drug molecules
  • Over 1,700  discontinued clinical studies of therapeutics can be considered as potential candidates for repurposing
  • In the pursuit of obtaining an edge within this emerging and highly competitive market landscape, service providers are actively exploring the therapeutic potential of the existing approved drugs by providing the necessary support to drug developers in identifying / predicting prospective drug candidates for repurposing.
  • Over time, recent initiatives have been undertaken by big pharma players across the world for the discovery and development of repurposed drugs
  • Several organizations have extended financial support to aid research efforts in this domain; the current focus is on investigation of novel immune checkpoint pathways / targets for coronavirus disease
  • The growing interest in this field is also reflected by the 10+ partnerships have been signed in the last three years, involving both international and indigenous stakeholders
  • The future market, based on the revenue generation potential of repurposed drugs, is anticipated to be distributed across different disease areas and key geographical regions
  • In the long term, the opportunity is likely to be segmented across type of repurposing approaches, purpose of repurposing and type of drug molecule

 

For more information, please visit https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html

 

Table of Contents

 

1.         PREFACE
1.1.       Scope of the Report
1.2.       Research Methodology
1.3.       Chapter Outlines

2.         EXECUTIVE SUMMARY


3.         INTRODUCTION
3.1.       Chapter Overview

3.2.       Overview of Drug Repurposing

3.2.1     History of Drug Repurposing

3.2.2     Strategies for Drug Repurposing

3.3.       Repurposing versus the Traditional Drug Discovery

3.4.       Benefits and Challenges Associated with Drug Repurposing       

3.5.       Drug Repurposing Service Providers

 

4.         MARKET LANDSCAPE

4.1.       Chapter Overview         

4.2.       Drug Repurposing Service Provider: Overall Market Landscape of Contract Research Organizations (CROs)

4.2.1.    Analysis by Year of Establishment

4.2.2.    Analysis by Company Size

4.2.3.    Analysis by Location of Headquarters

4.2.4.    Analysis by Company Size and Location of Headquarters

4.2.5.    Analysis by Type of Drug Molecule

4.2.6.    Analysis by Status of Drug

4.2.7.    Analysis by Repurposing Approach

4.2.8.    Analysis by Services Offered

 

4.3.       Drug Repurposing Service Provider: Overall Market Landscape of Big Data / Analytics Service Providers

4.3.1.    Analysis by Year of Establishment

4.3.2.    Analysis by Company Size

4.3.3.    Analysis by Location of Headquarters

4.3.4.    Analysis by Company Size and Location of Headquarters

4.3.5.    Analysis by Technology Specifications

4.3.6.    Analysis by Type of Drug Molecule

4.3.7.    Analysis by Status of Drug

4.3.8.    Analysis by Repurposing Approach

4.3.9.    Analysis by Services Offered

 

4.4.       Drug Repurposing Service Provider: Overall Market Landscape of Technology Providers

4.4.1.    Analysis by Year of Establishment

4.4.2.    Analysis by Company Size

4.4.3.    Analysis by Location of Headquarters

4.4.4.    Analysis by Company Size and Location of Headquarters

4.4.5.    Analysis by Technology Specifications

4.4.6.    Analysis by Type of Drug Molecule

4.4.7.    Analysis by Status of Drug

4.4.8.    Analysis by Repurposing Approach

4.2.9.    Analysis by Services Offered

 

5.         ROLE OF NON-PROFIT / ACADEMIC ORGANIZATIONS

5.1.       Chapter Overview

5.2.       Drug Repurposing Service Providers: List of Non-Profit Organizations

5.3.       Stakeholder Profiles

5.3.1.    Cures Within Reach

5.3.2.    GlobalCures

5.3.3.    Anticancer Fund

5.3.4.    National Center for Advancing Translational Sciences

5.4.       Drug Repurposing Service Providers: List of Academic Organizations

 

6.         COMPANY PROFILES

6.1.       Chapter Overview

6.2.       Company Profiles for CROs

6.2.1.    Auxiliis Pharma

6.2.1.1. Company Overview

6.2.1.2. Service Portfolio

6.2.1.3. Future Outlook

 

6.2.2.    ChemBio Discovery Solutions

6. 2.2.1. Company Overview

6. 2.2.2. Service Portfolio

6. 2.2.3. Future Outlook

 

6.2.3.    GVK BIO

6.2.3.1. Company Overview

6.2.3.2. Technology Overview

6.2.3.3. Service Portfolio

6.2.3.4. Future Outlook

 

6.2.4.    Iris Pharma

6.2.4.1. Company Overview

6.2.4.2. Service Portfolio

6.2.4.3. Future Outlook

 

6.2.5.    Physiogenex

6.2.5.1. Company Overview

6.2.5.2. Service Portfolio

6.2.5.3. Future Outlook

 

6.3.       Company Profiles for Big Data / Analytics Service Providers

6.3.1.    Excelra

6.3.1.1. Company Overview

6.3.1.2. Technology Overview

6.3.1.3. Service Portfolio

6.3.1.4. Future Outlook

 

6.3.2.    Smart Pharma

6.3.2.1. Company Overview

6.3.2.2. Technology Overview

6.3.2.3. Service Portfolio

6.3.2.4. Future Outlook

 

6.4.       Company Profiles for Technology Providers

6.4.1.    Lantern Pharma

6.4.1.1. Company Overview

6.4.1.2. Technology Overview

6.4.1.3. Service Portfolio

6.4.1.4. Future Outlook

 

6.4.2.    Panxome

6.4.2.1. Company Overview

6.4.2.2. Technology Overview

6.4.2.3. Service Portfolio

6.4.2.4. Future Outlook

 

6.4.3.    Pharmacelera

6.4.3.1. Company Overview

6.4.3.2. Technology Overview

6.4.3.3. Service Portfolio

6.4.3.4. Future Outlook

           

6.4.4.    Socium

6.4.4.1. Company Overview

6.4.4.2. Service Portfolio

6.4.4.3. Future Outlook

 

6.4.5.    SOM Biotech

6.4.5.1. Company Overview

6.4.5.2. Technology Overview

6.4.5.3. Service Portfolio

6.4.5.4. Future Outlook

           

7.         PARTNERSHIPS

7.1.       Chapter Overview

7.2.       Partnership Models

7.3.       Drug Repurposing Service Providers: List of Partnerships

7.3.1.    Analysis by Year of Partnership

7.3.2.    Analysis by Type of Partnership

7.3.3.    Analysis by Year and Type of Partnership

7.3.4.    Analysis by Type of Technology / Platform Used

7.3.5.    Analysis by Therapeutic Area

7.3.6.    Geographical Analysis

7.3.6.1. Continent-wise Distribution

7.3.6.2. Country-wise Distribution

 

8.         BIG PHARMA INITIATIVES

8.1.       Chapter Overview

8.2.       List of Drug Repurposing Initiatives of Big Pharma Players

8.2.1.    Analysis by Number of Initiatives

8.2.2.    Analysis by Year of Initiative

8.2.3.    Analysis by Type of Initiative

8.2.4.    Analysis by Therapeutic Area

8.2.5.    Analysis by Type of Drug Molecule

8.2.6.    Big Pharma Activity: Analysis by Year of Initiative and Company

8.2.7.    Big Pharma Activity: Analysis by Type of Drug Molecule and Company

 

8.3.       Competitive Benchmarking of Big Pharma Players

8.3.1.    Big Pharma Investment Summary

8.4.       Initiatives Undertaken by Leading Players

8.4.1.    Initiatives Undertaken by AbbVie

8.4.1.1. In-House Initiatives

 

8.4.2.    Initiatives Undertaken by Astellas Pharma

8.4.2.1. Initiatives in Collaboration with Other Stakeholders

8.4.2.2. Recent Regulatory Approvals of Repurposed Drugs

 

8.4.3.   Initiatives Undertaken By AstraZeneca

8.4.3.1. In-House Initiatives

8.4.3.2. Initiatives in Collaboration with Other Stakeholders

 

8.4.4.    Initiatives Undertaken by Bayer

8.4.4.1. Initiatives in Collaboration with Other Stakeholders

 

8.4.5.    Initiati



Category : general

Of course font size, and line height also play a role when deciding on readability, but for line length keep between the

Of course font size, and line height also play a role when deciding on readability, but for line length keep between the

- Perlis says that the common, insomnia-perpetuating error that most people commit is that they try to make up for lost sleep; they take naps, they go to bed early, and they sleep in late. “All of


PAGE TODAY VALLEY NEWS DISPATCH FRONT PAGE NEWS

PAGE TODAY VALLEY NEWS DISPATCH FRONT PAGE NEWS

- PAGE TODAY VALLEY NEWS DISPATCH FRONT PAGE NEWS NEWS FRONT ENGLISH NEWS FRONT ESPANOL ESNEWS FRO


Escape Room 2: Release date, cast, plot and everything you need to know

Escape Room 2: Release date, cast, plot and everything you need to know

- Escape Room 2 was an inevitable horror sequel as soon as the original movie grossed more than $150 million worldwide from a $9 million budget. pelicula


5 Surprising Benefits Of Using CBD As Supplement

5 Surprising Benefits Of Using CBD As Supplement

- Your body needs the right supply of minerals, vitamins, proteins, and other essential nutrients to enhance your immunity and keep you healthy.